emtricitabine and tenofovir disoproxil fumarate tablet, film coated
redpharm drug, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see clinical studies (14)] . emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection. individuals must have a negative hiv-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep [see dosage and administration (2.2), warnings and precautions (5.2)] . emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep is contraindicated in individuals with unknown or positive hiv-1 status [see warnings and precautions (5.2)] . pre
emtricitabine and tenofovir disoproxil fumarate tablet, film coated
pharmasource meds, llc - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see clinical studies ( 14)]. emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection. individuals must have a negative hiv-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep [see dosage and administration ( 2.2), warnings and precautions ( 5.2)]. emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep is contraindicated in individuals with unknown or positive hiv-1 status [ see warnings and precautions ( 5.2)]. pregnancy exposure registry there is a
emtricitabine and tenofovir disoproxil fumarate tablet, film coated
proficient rx lp - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see clinical studies (14)] . emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection. individuals must have a negative hiv-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep [see dosage and administration (2.2), warnings and precautions (5.2)] . emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep is contraindicated in individuals with unknown or positive hiv-1 status [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to emtricitabine and tenofovir disoproxil
emtricitabine and tenofovir disoproxil fumarate film-coated tablet
laurus labs limited 2nd floor, serene chambers, road no.-7 banjara - emtricitabine and tenofovir disoproxil fumarate - film-coated tablet - emtricitabine 200 mg and tenofovir disoproxil - tenofovir disoproxil and emtricitabine
emtricitabine and tenofovir disoproxil fumarate tablet
emtricitabine and tenofovir disoproxil fumarate - tablet - emtricitabine 200 mg and tenofovir disoproxil - tenofovir disoproxil and emtricitabine
ag-emtricitabine / tenofovir disoproxil fumarate tablet
angita pharma inc. - tenofovir disoproxil fumarate; emtricitabine - tablet - 300mg; 200mg - tenofovir disoproxil fumarate 300mg; emtricitabine 200mg - nucleoside and nucleotide reverse transcriptase inhibitors
emtricitabine/tenofovir disoproxil
teva pharma (new zealand) limited - emtricitabine 200mg; tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245mg; - film coated tablet - active: emtricitabine 200mg tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245mg excipient: croscarmellose sodium indigo carmine aluminium lake lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol pregelatinised maize starch purified talc purified water titanium dioxide - indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.
tenofovir disoproxil rowex 245 mg film-coated tablets
rowex ltd - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil
tenofovir disoproxil 245 mg film coated tablets
accord healthcare limited - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil
tenofovir disoproxil fumarate tablet, film coated
american health packaging - tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 2 years of age and older. the following points should be considered when initiating therapy with tenofovir disoproxil fumarate tablets for the treatment of hiv-1 infection: - tenofovir disoproxil fumarate tablets should not be used in combination with atripla ® , complera ® , descovy ® , genvoya ® , odefsey ® , stribild ® , truvada ® , or vemlidy ® [see warnings and precautions (5.4)]. tenofovir disoproxil fumarate tablets are indicated for the treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with tenofovir disoproxil fumarate tablets for the treatment of hbv infection: - the indication in adults is based on safety and efficacy data from treatment of subjects who were nucleoside-treatment-naïve and subjec